SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

FRA:SRT3 • DE0007165631

240.3 EUR
+2.4 (+1.01%)
Last: Feb 27, 2026, 05:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Taking everything into account, SRT3 scores 2 out of 10 in our fundamental rating. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. SRT3 has a bad profitability rating. Also its financial health evaluation is rather negative. SRT3 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SRT3 was profitable.
  • In the past year SRT3 had a positive cash flow from operations.
  • Of the past 5 years SRT3 4 years were profitable.
  • SRT3 had a positive operating cash flow in 4 of the past 5 years.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • With a Return On Assets value of 1.39%, SRT3 is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • The Return On Equity of SRT3 (5.01%) is worse than 72.22% of its industry peers.
  • The Return On Invested Capital of SRT3 (4.71%) is worse than 77.78% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 9.63%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.80%, SRT3 is doing worse than 77.78% of the companies in the same industry.
  • SRT3's Profit Margin has declined in the last couple of years.
  • SRT3's Operating Margin of 14.06% is in line compared to the rest of the industry. SRT3 outperforms 50.00% of its industry peers.
  • SRT3's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 46.48%, SRT3 is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SRT3 has declined.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SRT3 is creating some value.
  • SRT3 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • SRT3 has an Altman-Z score of 2.42. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • SRT3's Altman-Z score of 2.42 is in line compared to the rest of the industry. SRT3 outperforms 50.00% of its industry peers.
  • SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
  • SRT3 has a Debt to FCF ratio of 8.92. This is in the lower half of the industry: SRT3 underperforms 66.67% of its industry peers.
  • A Debt/Equity ratio of 1.28 is on the high side and indicates that SRT3 has dependencies on debt financing.
  • SRT3 has a worse Debt to Equity ratio (1.28) than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.42
ROIC/WACC0.57
WACC8.25%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • SRT3 has a Current Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.95, SRT3 is doing worse than 83.33% of the companies in the same industry.
  • SRT3 has a Quick Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SRT3 has a Quick ratio of 0.49. This is amonst the worse of the industry: SRT3 underperforms 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • SRT3 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.76% yearly.
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.97% on average over the next years. This is quite good.
  • SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.68% yearly.
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SRT3 is valuated quite expensively with a Price/Earnings ratio of 50.27.
  • Compared to the rest of the industry, the Price/Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 83.33% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.10, SRT3 is valued quite expensively.
  • A Price/Forward Earnings ratio of 39.71 indicates a quite expensive valuation of SRT3.
  • 77.78% of the companies in the same industry are cheaper than SRT3, based on the Price/Forward Earnings ratio.
  • SRT3's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 50.27
Fwd PE 39.71
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SRT3 is valued a bit more expensive than 61.11% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRT3 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 37.6
EV/EBITDA 23.61
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as SRT3's earnings are expected to grow with 20.79% in the coming years.
PEG (NY)1.89
PEG (5Y)28.51
EPS Next 2Y23.47%
EPS Next 3Y20.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • SRT3 has a yearly dividend return of 0.38%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.44, SRT3 has a dividend in line with its industry peers.
  • With a Dividend Yield of 0.38, SRT3 pays less dividend than the S&P500 average, which is at 1.83.
Industry RankSector Rank
Dividend Yield 0.38%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 37.92% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP37.92%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SARTORIUS AG-VORZUG

FRA:SRT3 (2/27/2026, 5:36:15 PM)

240.3

+2.4 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.99B
Revenue(TTM)N/A
Net Income(TTM)133.70M
Analysts80
Price Target376.45 (56.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.38%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.73%
PT rev (3m)9.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE 50.27
Fwd PE 39.71
P/S 5.12
P/FCF 37.6
P/OCF 20.58
P/B 6.74
P/tB N/A
EV/EBITDA 23.61
EPS(TTM)4.78
EY1.99%
EPS(NY)6.05
Fwd EY2.52%
FCF(TTM)6.39
FCFY2.66%
OCF(TTM)11.68
OCFY4.86%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)1.89
PEG (5Y)28.51
Graham Number61.91
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.42
F-Score7
WACC8.25%
ROIC/WACC0.57
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y26.59%
EPS Next 2Y23.47%
EPS Next 3Y20.79%
EPS Next 5Y15.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%2.29%
Revenue Next Year7.13%
Revenue Next 2Y8.81%
Revenue Next 3Y9.38%
Revenue Next 5Y8.68%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.23%
EBIT Next 3Y36.56%
EBIT Next 5Y25.33%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 50.27 and the Price/Book (PB) ratio is 6.74.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.